Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyViva Health Krystexxa Prior Auth & Coverage | Open…
    Ask Trek AI about this page
    CurrentViva HealthPolicy IC-0158

    Krystexxa (pegloticase) — Prior Authorization and Coverage Criteria

    Customize your policy alerts

    Sign up for Viva Health Policy IC-0158 alerts

    Get alerted when Policy IC-0158 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines prior authorization, dosing limits, initial and renewal medical necessity criteria, and billing/coding for intravenous Krystexxa (pegloticase) for members eligible under Viva Health.

    Policy Summary
    PayerViva Health
    PolicyKrystexxa (pegloticase) — Prior Authorization and Coverage Criteria
    Policy CodePolicy IC-0158
    Change TypeNo material changes
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateJul 1, 2026
    Key ActionSubmit prior authorization with baseline serum uric acid (≥7 mg/dL) and documentation of prior 3-month trial of xanthine oxidase inhibitor or uricosuric therapy.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    6 monthsinitial prior authorization duration
    12 monthsrenewal prior authorization validity
    16max billable units / 28 days
    8 mg q2wrecommended dosing

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    J2507HCPCS code (1 mg/unit)

    Coverage criteria for Krystexxa (pegloticase)

    Initial Therapy

    Covered when ALL of the following are met:

    Age and contraindications: Member is at least 18 years of age AND member does NOT have any FDA labeled contraindications to the requested agent (e.g., deficiency in glucose-6-phosphate dehydrogenase [G6PD], history of serious hypersensitivity reaction to Krystexxa or any of its components).
    Baseline lab: Documentation of baseline serum uric acid level >= 7 mg/dL (current lab reports are required for renewal).>= 7 mg/dL
    Medication combination restriction: Therapy will not be given in combination with other urate lowering therapies such as allopurinol, febuxostat, probenecid, etc.
    Prior therapy requirement for chronic gout: Documented contraindication, intolerance, or clinical failure (inability to reduce serum uric acid to < 6 mg/dL) during a minimum 3-month trial on previous therapy with maximum tolerated dose of xanthine oxidase inhibitors (e.g., allopurinol or febuxostat) or uricosuric agents; AND used in combination with methotrexate OR as a single agent if methotrexate is contraindicated or not clinically appropriate; AND member has 2+ gout flares/year despite prophylaxis OR at least one non-resolving subcutaneous tophus OR radiographic damage attributable to gout.

    Renewal Criteria

    Renewal may be approved when ALL of the following are met:

    Ongoing criteria: Member continues to meet the universal and indication-specific criteria identified for initial approval.
    Clinical response: Disease response with treatment (reduction of symptoms, reduction of tophi).
    Toxicity absence: Absence of unacceptable toxicity from the drug (e.g., anaphylaxis, infusion reactions, exacerbation of congestive heart failure, hemolytic reactions including methemoglobinemia and hemolysis).
    Lab requirement: Documentation of serum uric acid level <= 6 mg/dL prior to scheduled infusion.<= 6 mg/dL

    Therapy with pegloticase must not be administered in combination with other urate‑lowering therapies. The policy explicitly prohibits concurrent use with agents such as allopurinol, febuxostat, probenecid because combination use is not supported by the coverage criteria and raises safety/efficacy concerns. In addition, providers should note there is no controlled trial data supporting safe retreatment after a drug‑free interval >4 weeks; due to the drug’s immunogenicity, retreatment carries an increased risk of anaphylaxis and infusion reactions and requires careful monitoring.

    When pegloticase is used for chronic gout, it is expected to be started with appropriate gout flare prophylaxis and—when indicated—co‑administered with methotrexate to improve response. The policy requires documentation that prior medication trials and concomitant treatment decisions meet the indication‑specific requirements (see initial and renewal criteria).

    This policy section applies to non‑Medicare coverage determinations. Providers billing Medicare Part B should consult CMS guidance for applicable National Coverage Determinations (NCDs), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) prior to submitting claims. The policy’s Appendix 2 points users to the CMS Coverage Database (https://www.cms.gov/medicare-coverage-database/search.aspx) for jurisdiction‑specific Part B coverage rules; the appendix notes that in this document segment the listed Medicare Part B covered diagnosis codes are N/A.

    Include the appropriate Medicare‑applicable codes and documentation on claims when Medicare guidance applies; where a Medicare NCD/LCD/LCA exists, compliance with that Medicare policy is required.

    Initial approval requires documentation of an adequate prior trial of xanthine oxidase inhibitors or uricosuric agents unless clearly contraindicated or not tolerated. Specifically, the member must have a documented contraindication, intolerance, or clinical failure (inability to reduce serum uric acid to < 6 mg/dL) after a minimum 3‑month trial at maximum tolerated doses of agents such as allopurinol or febuxostat, or a uricosuric (e.g., probenecid).

    Age and contraindication exceptions: the member must be at least 18 years old and must not have FDA‑labeled contraindications (for example, G6PD deficiency or a history of serious hypersensitivity to pegloticase). Requests for members younger than 18 years, or for members with those contraindications, do not meet initial medical necessity criteria per this policy.

    Billing, codes and lab thresholds

    HCPCS CodeHCPCSCovered
    J2507Injection, pegloticase, 1 mg; 1 billable unit = 1mg
    NDCsNDC
    75987-0058-xxKrystexxa 8 mg/50 mL (0.16 mg/mL) Ready-to-Use single-dose vial
    75987-0080-xxKrystexxa 8 mg/mL To-be-Diluted single-dose vial
    Covered ICD-10 Codes (sample listing)ICD-10Covered
    M1A.00X0Idiopathic chronic gout, unspecified site, without tophus (tophi).
    M1A.00X1Idiopathic chronic gout, unspecified site, with tophus (tophi).
    Covered ICD-10 Diagnosis Codes (Appendix 1 segment)ICD-10Covered
    M1A.0620Idiopathic chronic gout, left knee, without tophus (tophi).
    M1A.0621Idiopathic chronic gout, left knee, with tophus (tophi).
    M1A.0690Idiopathic chronic gout, unspecified knee, without tophus (tophi).
    M1A.0691Idiopathic chronic gout, unspecified knee, with tophus (tophi).
    M1A.0710Idiopathic chronic gout, right ankle and foot, without tophus (tophi).
    M1A.0711Idiopathic chronic gout, right ankle and foot, with tophus (tophi).
    M1A.0720Idiopathic chronic gout, left ankle and foot, without tophus (tophi).
    M1A.0721Idiopathic chronic gout, left ankle and foot, with tophus (tophi).
    M1A.0790Idiopathic chronic gout, unspecified ankle and foot, without tophus (tophi).
    M1A.0791Idiopathic chronic gout, unspecified ankle and foot, with tophus (tophi).
    1–10 of 112
    1/12
    Serum uric acid thresholds
    Initial serum uric acid thresholdBaseline serum uric acid >= 7 mg/dL (current labs required for renewal)
    Renewal serum uric acid thresholdDocumentation of serum uric acid <= 6 mg/dL prior to scheduled infusion
    Measurement requirementCurrent laboratory reports must be submitted for renewal to confirm sUA levels

    What providers must do

    Prior Authorization

    Obtain prior authorization and submit supporting labs

    Prior authorization is required. Initial approvals are valid for 180 days (6 months); renewals may be approved every 365 days (12 months). Submit supporting laboratory results and documentation described in the initial and renewal criteria with the prior authorization request.

    • Include baseline serum uric acid (sUA) for initial requests and current sUA for renewals.
    • Reference HCPCS J2507 on claims (injection, pegloticase, 1 mg).
    Note

    Verify Medicare (Part B) coverage and local CMS policies

    Check CMS guidance for Medicare Part B coverage where applicable. Use the CMS Medicare Coverage Database to identify any applicable NCDs, LCDs, or LCAs that govern Part B reimbursement and coverage determinations.

    • Search NCD/LCD/LCA documents at https://www.cms.gov/medicare-coverage-database/search.aspx.
    • Medicare Part B Covered Diagnosis Codes in this document are listed as N/A — verify local Medicare coverage guidance prior to billing.

    Background and drug information

    Krystexxa (pegloticase) is an intravenous, pegylated uricase indicated for refractory chronic gout in adults. It enzymatically converts uric acid to allantoin, lowering serum uric acid in patients who have not achieved target levels with conventional therapies. The drug is immunogenic and associated with infusion‑related reactions and potentially serious hemolytic events; the policy specifically highlights the risk in patients with G6PD deficiency and requires exclusion of members with FDA‑labeled contraindications.

    Recommended dosing for chronic gout in this policy is 8 mg IV every 2 weeks; gout flare prophylaxis should begin at least one week before initiation and continue for at least six months unless contraindicated. When used with methotrexate, methotrexate should be started (typically weekly oral 15 mg with folic/folinic acid supplementation) at least four weeks before initiating pegloticase to improve response and reduce immunogenicity.

    Because pegloticase is immunogenic, there is no controlled trial data supporting retreatment after stopping therapy for more than four weeks; retreatment after a drug‑free interval may increase the risk of anaphylaxis and infusion reactions and therefore requires careful monitoring.

    Key definitions used in this policy

    Refractory chronic gout — failure/intolerance criteria
    Minimum prior trial durationMinimum 3-month trial on previous therapy with maximum tolerated dose of xanthine oxidase inhibitors or uricosuric agents
    Definition of clinical failureInability to reduce serum uric acid to < 6 mg/dL during the prior trial
    Concomitant therapy requirementUsed in combination with methotrexate OR as a single agent if methotrexate is contraindicated or not clinically appropriate
    Additional clinical criteriaMember has ≥2 gout flares/year despite prophylaxis OR ≥1 non-resolving subcutaneous tophus OR radiographic damage attributable to gout
    FDA‑labeled contraindications
    G6PD deficiencyDeficiency in glucose-6-phosphate dehydrogenase (G6PD) is an FDA‑labeled contraindication
    Policy Summary
    PayerViva Health
    PolicyKrystexxa (pegloticase) — Prior Authorization and Coverage Criteria
    Policy CodePolicy IC-0158
    Change TypeNo material changes
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateJul 1, 2026
    Key ActionSubmit prior authorization with baseline serum uric acid (≥7 mg/dL) and documentation of prior 3-month trial of xanthine oxidase inhibitor or uricosuric therapy.
    SourceLink
    On This Page
    Coverage criteria for Krystexxa (pegloticase)Billing, codes and lab thresholdsWhat providers must doBackground and drug informationKey definitions used in this policy
    Maintenance necessity: Continuation of therapy is necessary to maintain response/remission.
    Step Therapy

    Document prior medication trial of xanthine oxidase inhibitor or uricosuric for ≥3 months

    Document a minimum 3-month trial of maximally tolerated xanthine oxidase inhibitors (e.g., allopurinol or febuxostat) or uricosuric agents unless the member is intolerant or has a contraindication.

    • Record trial duration (≥3 months), medication names, doses, and reason for failure/intolerance or contraindication.
    Note

    Provider note: use Appendix 1 and follow policy sections for documentation

    Providers must note that Appendix 1 lists covered ICD-10 diagnosis codes and that the policy requires clinical documentation per the criteria in sections III and IV (see referenced policy sections).

    • Appendix 1 contains the specific covered ICD-10 codes to reference on requests and claims.
    • Ensure clinical documentation aligns with the policy’s initial and renewal criteria.
    Documentation Required

    Submit baseline and renewal labs plus prior-trial and concomitant therapy documentation

    Provide required clinical documentation with the PA request and for renewals: baseline serum uric acid ≥ 7 mg/dL for initial authorization; for renewal, documentation of sUA ≤ 6 mg/dL prior to scheduled infusion, evidence of clinical response, and absence of unacceptable toxicity.

    • Document prior trials of xanthine oxidase inhibitors or uricosurics (≥3 months) including inability to reduce sUA <6 mg/dL when applicable.
    • Include current laboratory reports with dates and values for both initial and renewal requests.
    Billing Rule

    Include an Appendix 1 ICD-10 diagnosis code on requests and claims

    Include an appropriate ICD-10 diagnosis code from Appendix 1 on the prior authorization and on claims to support medical necessity for Krystexxa (pegloticase).

    • Appendix 1 lists the covered diagnosis codes (e.g., the M1A.* series) to select the applicable code.
    • Ensure the diagnosis code matches the clinical documentation provided.
    Denial Risk

    Do not request therapy for members <18 or with FDA‑labeled contraindications

    Requests for members under 18 years of age or members with FDA-labeled contraindications (e.g., G6PD deficiency or history of serious hypersensitivity to Krystexxa) will not meet initial criteria and should be denied or require exception documentation.

    • Confirm member age ≥18 on the request.
    • Document absence of FDA-labeled contraindications (e.g., G6PD deficiency, serious hypersensitivity).
    Denial Risk

    Demonstrate failure/intolerance to alternatives and document concomitant therapy for renewals

    For renewals, document clinical failure, intolerance, or contraindication to alternative therapies and confirm required concomitant therapy status (e.g., methotrexate co-administration when indicated) or justify why methotrexate is not used.

    • Provide evidence of clinical response (reduction of symptoms/tophi) and sUA ≤ 6 mg/dL prior to infusion.
    • If methotrexate is not used, document contraindication or clinical rationale for single-agent use.
    Note

    Ensure Medicare claims comply with applicable NCDs/LCDs/LCAs

    Claims for Medicare beneficiaries may be subject to applicable NCDs, LCDs, or LCAs; providers must ensure compliance with those Medicare policies where they exist in addition to the plan’s non‑Medicare criteria.

    • Use the CMS Medicare Coverage Database to identify relevant NCDs/LCDs/LCAs prior to billing for Part B.
    • The policy’s preceding information is intended for non‑Medicare coverage determinations; verify Medicare-specific rules before submission.
    Serious hypersensitivity historyHistory of serious hypersensitivity reaction to Krystexxa or any of its components is an FDA‑labeled contraindication
    Age-related contraindication noteRequests for members younger than 18 years will not meet initial criteria (member must be at least 18 years of age)